Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in the prevention of the mosquito-borne virus dengue, confirming its ability to convey protection against virologically-confirmed cases in paediatric patients from four to 16 years old.
In the 12-month period following the second dose of the vaccine, which was administered three months after the first dose, Takeda’s product was found to be 80.2% effective.
